- Home
- AMED vs PTGX Comparison
AMED vs PTGX Comparison
Compare AMED & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMED
- PTGX
- Stock Information
- Founded
- AMED 1982
- PTGX 2006
- Country
- AMED United States
- PTGX United States
- Employees
- AMED N/A
- PTGX N/A
- Industry
- AMED Medical/Nursing Services
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- AMED Health Care
- PTGX Health Care
- Exchange
- AMED Nasdaq
- PTGX Nasdaq
- Market Cap
- AMED 3.2B
- PTGX 3.3B
- IPO Year
- AMED N/A
- PTGX 2016
- Fundamental
- Price
- AMED $97.18
- PTGX $53.00
- Analyst Decision
- AMED Hold
- PTGX Strong Buy
- Analyst Count
- AMED 5
- PTGX 9
- Target Price
- AMED $100.80
- PTGX $67.11
- AVG Volume (30 Days)
- AMED 486.4K
- PTGX 923.4K
- Earning Date
- AMED 07-23-2025
- PTGX 08-05-2025
- Dividend Yield
- AMED N/A
- PTGX N/A
- EPS Growth
- AMED N/A
- PTGX N/A
- EPS
- AMED 2.72
- PTGX 0.86
- Revenue
- AMED $2,371,691,000.00
- PTGX $207,801,000.00
- Revenue This Year
- AMED $6.29
- PTGX N/A
- Revenue Next Year
- AMED $5.25
- PTGX $53.09
- P/E Ratio
- AMED $35.97
- PTGX $61.48
- Revenue Growth
- AMED 5.34
- PTGX N/A
- 52 Week Low
- AMED $82.15
- PTGX $32.50
- 52 Week High
- AMED $98.95
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- AMED 54.07
- PTGX 53.99
- Support Level
- AMED $95.55
- PTGX $49.38
- Resistance Level
- AMED $97.92
- PTGX $51.51
- Average True Range (ATR)
- AMED 0.70
- PTGX 2.02
- MACD
- AMED -0.11
- PTGX -0.39
- Stochastic Oscillator
- AMED 55.44
- PTGX 46.09
About AMED Amedisys Inc
Amedisys Inc is a healthcare services company in the United States. The company brings healthcare to the home through the provision of home healthcare services, hospice services, and high acuity care segment. The Home Health Segment provides skilled nurses, therapists, and aids to patients' homes throughout the United States; the Hospice segment operates many centers designed to provide comfort and support for terminally ill patients; and the High acuity care segment can deliver the essential elements of inpatient hospital, SNF care, and palliative care to patients in their homes. A majority of the company's revenue is derived from the Home Health segment.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.